Last reviewed · How we verify
RLF-OD032
At a glance
| Generic name | RLF-OD032 |
|---|---|
| Also known as | Sapropterin dihydrochloride |
| Sponsor | APR Applied Pharma Research s.a. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study on Sapropterin Dihydrochloride Oral Suspension in Healthy Subjects (PHASE1)
- Study on Sapropterin Dihydrochloride Oral Suspension in Healthy Subjects Under Fed Conditions (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RLF-OD032 CI brief — competitive landscape report
- RLF-OD032 updates RSS · CI watch RSS
- APR Applied Pharma Research s.a. portfolio CI